Jennison Associates
AGIO icon

Jennison Associates’s Agios Pharmaceuticals AGIO Stock Holding History

Jennison Associates’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-357,111
Closed -$12.5M – 640
2020
Q3 		$12.5M Buy
357,111
+3,994
+1% +$175K 0.01% 358
2020
Q2 		$18.9M Sell
353,117
-199,612
-36% -$9.24M 0.02% 305
2020
Q1 		$19.6M Buy
552,729
+4,376
+0.8% +$202K 0.02% 254
2019
Q4 		$26.2M Buy
548,353
+4,749
+0.9% +$179K 0.03% 274
2019
Q3 		$17.6M Sell
543,604
-54,235
-9% -$2.25M 0.02% 329
2019
Q2 		$29.8M Buy
597,839
+212,949
+55% +$11.4M 0.03% 287
2019
Q1 		$26M Buy
384,890
+191,359
+99% +$11.1M 0.03% 319
2018
Q4 		$8.92M Sell
193,531
-1,839
-0.9% -$114K 0.01% 444
2018
Q3 		$15.1M Buy
195,370
+1,435
+0.7% +$115K 0.01% 432
2018
Q2 		$16.3M Buy
193,935
+3,183
+2% +$278K 0.02% 426
2018
Q1 		$15.6M Buy
190,752
+24,497
+15% +$1.89M 0.02% 422
2017
Q4 		$9.51M Buy
166,255
+190
+0.1% +$12K 0.01% 466
2017
Q3 		$11.1M Sell
166,065
-390
-0.2% -$23.4K 0.01% 473
2017
Q2 		$8.56M Sell
166,455
-3,344
-2% -$171K 0.01% 493
2017
Q1 		$9.92M Hold
169,799
– – 0.01% 487
2016
Q4 		$7.09M Buy
169,799
+547
+0.3% +$28.7K 0.01% 497
2016
Q3 		$8.94M Sell
169,252
-722
-0.4% -$31.4K 0.01% 481
2016
Q2 		$7.12M Sell
169,974
-312,123
-65% -$15.4M 0.01% 486
2016
Q1 		$19.6M Buy
482,097
+52,012
+12% +$2.22M 0.02% 406
2015
Q4 		$27.9M Buy
430,085
+271,142
+171% +$17.8M 0.03% 379
2015
Q3 		$11.2M Buy
158,943
+994
+0.6% +$97.2K 0.01% 502
2015
Q2 		$17.6M Buy
157,949
+1,272
+0.8% +$137K 0.02% 468
2015
Q1 		$14.8M Buy
156,677
+400
+0.3% +$44.8K 0.01% 469
2014
Q4 		$17.5M Sell
156,277
-81,148
-34% -$7.25M 0.02% 449
2014
Q3 		$14.6M Buy
237,425
+186
+0.1% +$8.02K 0.01% 461
2014
Q2 		$10.9M Sell
237,239
-72,168
-23% -$2.94M 0.01% 473
2014
Q1 		$12.1M Buy
309,407
+2,172
+0.7% +$72.7K 0.01% 480
2013
Q4 		$7.36M Buy
307,235
+132,235
+76% +$3.01M 0.01% 496
2013
Q3 		$4.89M Buy
+175,000
New +$4.83M 0.01% 509

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates's AGIO Position: Q4 2020 in Review

Jennison Associates sold out of Agios Pharmaceuticals (AGIO) in Q4 2020, closing a stake of 357,111 shares — an estimated $12.5M sold.

Jennison Associates first reported a position in AGIO in Q3 2013 and held it in 29 quarters. The position peaked at $29.8M in Q2 2019. 200 funds tracked by Wall St. Rank hold AGIO as of Q4 2020.

  • Jennison Associates reported no remaining Agios Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Jennison Associates sold 357,111 Agios Pharmaceuticals shares in Q4 2020, an estimated $12.5M.
  • Jennison Associates first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 29 quarters.
  • Jennison Associates's Agios Pharmaceuticals position peaked at $29.8M in Q2 2019.
  • 200 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2020.

Based on Jennison Associates's 13F filing for Q4 2020, filed 5 Feb 2021.